Arimoclomol
- Generic Name
- Arimoclomol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20ClN3O3
- CAS Number
- 289893-25-0
- Unique Ingredient Identifier
- EUT3557RT5
- Background
Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
- Indication
Investigated for use/treatment in amyotrophic lateral sclerosis (ALS), diabetes mellitus type 2, neurologic disorders, and neuropathy (diabetic).
- Associated Conditions
- -
- Associated Therapies
- -
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
- Conditions
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- CytRx
- Target Recruit Count
- 80
- Registration Number
- NCT00244244
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.